News & Updates
Filter by Specialty:
Adjuvant trastuzumab for HER2-positive early BC: 9 weeks or 1 year?
For patients with HER2-positive early breast cancer (BC), 1 year of adjuvant trastuzumab remains standard of care (SoC) as noninferiority is not demonstrated for a shortened 9-week course of treatment in the final analysis of the phase III ShortHER trial. However, long-term data from the trial provide reassurance in case early discontinuation is needed in low-risk patients.
Adjuvant trastuzumab for HER2-positive early BC: 9 weeks or 1 year?
05 Oct 2023
Increasing BP level in late adolescence ups risk of cardiovascular events
Rising levels of blood pressure (BP), starting at 120/80 mm Hg, during late adolescence contribute to a gradual elevation in the risk of major cardiovascular events, reports a study in Sweden.
Increasing BP level in late adolescence ups risk of cardiovascular events
04 Oct 2023
Combination therapy with olmesartan safe, effective in advanced hypertension
Use of olmesartan in a combination therapy for advanced hypertension results in similar cardiovascular outcomes, including myocardial infarction (MI), relative to active comparators, according to a study. Additionally, there is no convincing evidence that olmesartan is harmful to patients with hypertension.
Combination therapy with olmesartan safe, effective in advanced hypertension
04 Oct 2023
COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?
Mental health symptoms of family members of patients hospitalized for acute respiratory distress syndrome (ARDS) were similar at 12 months regardless of whether it was caused by COVID-19 or not, a prospective cohort study suggests.
